New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTNPSP, HSP, AKRX, UTHR, MDVN, CBST, ALKS, SLXP, JAZZ, AUXLLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:46 EDTAKRXAkorn remains a potential takeout target, says RBC Capital
RBC Capital analyst Randall Stanicky says he remains optimistic that Akorn (AKRX) can complete the audit process by May 9 and that the company remains a potential takeout candidate despite one less near-term buyer in Mylan (MYL). Mylan's purchase of Meda puts a potential buyer on the sidelines for now, Stanicky tells investors in a research note. He had viewed Mylan as the most likely suitor followed by Perrigo (PRGO). Applying the price paid for Meda yields a $47 per share buyout price target for Akorn, the analyst notes. He lowered his price target for Akorn shares to $37 from $52 and keeps an Outperform rating on the name.
February 11, 2016
07:17 EDTALKSLeerink to hold a conference
Subscribe for More Information
February 10, 2016
12:47 EDTUTHRUnited Therapeutics upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
07:04 EDTALKSAlkermes announces initiation of second Phase 3 study of ALKS 3831
Subscribe for More Information
February 9, 2016
09:07 EDTALKSAlkermes CEO remains optimistic on depression drug, Forbes reports
Subscribe for More Information
February 5, 2016
09:26 EDTMDVNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:51 EDTALKSWoodford calls Alkermes, Prothena selloffs 'greatly overdone'
British businessman Neil Woodford's Woodford Investment Management said it added to Alkermes (ALKS) and Prothena (PRTA) positions at what it considers to be "extremely attractive valuation levels." In its January letter to investors, the fund says the recent share price moves "look greatly overdone." Woodford also sold its position in GlaxoSmithKline (GSK) and initiated a new stake in Theravance Biopharma (TBPH). The company "retains a valuable economic interest in the future commercial potential of the respiratory franchise being developed in partnership with GlaxoSmithKline," the fund wrote. It also has "some very interesting, albeit earlier-stage, assets in therapeutic areas such as chronic obstructive pulmonary disease, cardiovascular & renal disease," it added. Woodford made no mention of Northwest Biotherapeutics (NWBO) in the letter, a company he invested in last year. Woodford Investment Management, established in 2014, describes itself as the "the opportunity for Neil Woodford, one of the UK's most highly-regarded fund managers, to distil his 30 years of experience and learning into a business founded on his own principles." Reference Link
06:05 EDTMDVNMedivation resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:36 EDTMDVNMedivation reinitiated with a Market Perform at Leerink
Target $41.
February 2, 2016
08:59 EDTALKSLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
February 1, 2016
09:08 EDTJAZZJazz Pharmaceuticals reports data from Phase 3 pivotal study of defibrotide
Jazz Pharmaceuticals announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology, or ASH. The data demonstrated that defibrotide use in patients with hepatic veno-occlusive, or VOD, also known as sinusoidal obstruction syndrome, with multi-organ failure post-hematopoietic stem-cell transplantation was associated with a statistically significant improvement in Day +100 survival and in rate of complete response by Day +100, compared with rigorously selected historical controls.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use